Cost-effectiveness of enzyme replacement therapy for Fabry disease

[1]  Wei Zheng,et al.  ENZYME REPLACEMENT THERAPY FOR FABRY DISEASE , 2013 .

[2]  W. Henley,et al.  The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. , 2012, Health technology assessment.

[3]  S. Vegter,et al.  Using a genetic, observational study as a strategy to estimate the potential cost-effectiveness of pharmacological CCR5 blockade in dialysis patients , 2011, Pharmacogenetics and genomics.

[4]  S. Simoens.  Pricing and reimbursement of orphan drugs: the need for more transparency , 2011, Orphanet journal of rare diseases.

[5]  T. Cox,et al.  Orphan drug pricing may warrant a competition law investigation , 2010, BMJ : British Medical Journal.

[6]  D. Bichet,et al.  Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative. , 2010, Molecular genetics and metabolism.

[7]  Y. Chien,et al.  Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later‐onset GLA mutation c.936+919G>A (IVS4+919G>A) , 2009, Human mutation.

[8]  A. Garg,et al.  Angiotensin inhibition in renovascular disease: a population-based cohort study. , 2008, American heart journal.

[9]  R. Brady,et al.  Elevated globotriaosylsphingosine is a hallmark of Fabry disease , 2008, Proceedings of the National Academy of Sciences.

[10]  G. Sommer,et al.  Reference , 2008 .

[11]  J. M. Aerts,et al.  Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg , 2007, PloS one.

[12]  J. Charrow,et al.  Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. , 2007, Journal of the American Society of Nephrology : JASN.

[13]  F. Bemelman,et al.  The Dutch Fabry cohort: Diversity of clinical manifestations and Gb3 levels , 2007, Journal of Inherited Metabolic Disease.

[14]  R. Desnick,et al.  High incidence of later-onset fabry disease revealed by newborn screening. , 2006, American journal of human genetics.

[15]  M. Connock,et al.  A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1. , 2006, Health technology assessment.

[16]  D. Hughes,et al.  Drugs for exceptionally rare diseases: do they deserve special status for funding? , 2005, QJM : monthly journal of the Association of Physicians.

[17]  M. Postma,et al.  Need for differential discounting of costs and health effects in cost effectiveness analyses , 2005, BMJ : British Medical Journal.

[18]  Paul F. M. Krabbe,et al.  Kwaliteit van leven meten in economische evaluaties: het Nederlands EQ-5D-tarief , 2005 .

[19]  A. Mehta,et al.  Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey) , 2005, Journal of Medical Genetics.

[20]  J. Kriegsmann,et al.  Anderson–Fabry disease: Clinical manifestations of disease in female heterozygotes , 2001, Journal of Inherited Metabolic Disease.

[21]  K. Macdermot,et al.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males , 2001, Journal of medical genetics.

[22]  K. Macdermot,et al.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females , 2001, Journal of medical genetics.

[23]  S. Yusuf,et al.  Effects of Ramipril on Coronary Events in High-Risk Persons: Results of the Heart Outcomes Prevention Evaluation Study , 2001, Circulation.

[24]  S. Yusuf,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[25]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[26]  Andrew Briggs,et al.  An Introduction to Markov Modelling for Economic Evaluation , 1998, PharmacoEconomics.

[27]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[28]  S. Tsuji.  [Alpha-galactosidase A deficiency--Fabry's disease]. , 1988, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[29]  J. Brecht,et al.  Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular Events , 2012, PharmacoEconomics.

[30]  M. Pitt,et al.  Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. , 2012, Health technology assessment.

[31]  R. Schiffmann,et al.  Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson disease. , 2007, PharmacoEconomics.

[32]  E. C. Ham.  Body composition and exercise intolerance in renal transplant patients: the response to exercise training , 2006 .

[33]  S. Packman,et al.  Agalsidase-Beta Therapy for Advanced Fabry Disease A Randomized Trial , 2006 .

[34]  P. Stalmeier,et al.  [Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff]. , 2005, Nederlands tijdschrift voor geneeskunde.

[35]  D. Blom,et al.  Recombinant Enzyme Therapy for Fabry Disease: Absence of Editing of Human α-Galactosidase A mRNA , 2003 .

[36]  D. Blom,et al.  UvA-DARE ( Digital Academic Repository ) Recombinant enzyme therapy for Fabry disease : absence of editing of human alpha-galactosidase A mRNA , 2002 .

[37]  Z. Stark,et al.  Orphanet Journal of Rare Diseases , 2022 .

[38]  S. Simoens.  Clinicoeconomics and Outcomes Research Dovepress Biosimilar Medicines and Cost-effectiveness , 2022 .